目的 觀察卡馬西平聯(lián)合寧癇丹治療癲癇的臨床療效及安全性。方法 將42例癲癇患者隨機(jī)分為治療組和對照組。對照組服用卡馬西平，13歲兒童～成人0.2 g/次，3次/d，6～12歲兒童10～20 mg/(kg?d?1)，分3次服用；治療組服用卡馬西平的用法及用量同對照組，另外治療組患者口服寧癇丹，6歲患兒3 丸/d，7～10歲4～6丸/d，10～14歲6～9丸/d，15歲～成人9～l2丸/d，分3次服用。兩組均持續(xù)治療3個月。治療結(jié)束后，觀察兩組患者臨床療效、癲癇發(fā)作次數(shù)、治療前后腦電圖異常情況。結(jié)果 兩組治療后癲癇發(fā)作次數(shù)、腦電圖異常與治療前比較差異均有統(tǒng)計學(xué)意義（P＜0.05），治療組和對照組總有效率分別為95.24%、66.67%，兩組比較差異有統(tǒng)計學(xué)意義（P＜0.05）。結(jié)論 卡馬西平聯(lián)合寧癇丹治療癲癇可減少患者癲癇發(fā)作次數(shù)，且不良反應(yīng)較少，值得臨床推廣。

Objective To evaluate the clinical efficiency and security of carbamazepine combined with Ningxian Powder in the treatment of epilepsy. Methods The patients (42 cases) diagnosed as epilepsy were randomly divided into treatment (21 cases) and control (21 cases) groups. The patients in the control group were po administered with carbamazepine, from 13-years old to adult 0.2 g/time and 6—12-years old 10—20 mg/(kg?d?1), for three times daily. The usage and dosage of carbamazepine in the two groups were the same. The patients in the treatment group were po administered with Ningxian Powder, 6-years old children 3 pills/d, 7—10-years old 4—6 pills/d, 10—14-years old 6—9 pills/d, and from 15-years old to adult 9—l2 pills/d for 3－4 doses, daily. The patients in the two groups were treated for three months. At the end of the treatment, the therapeutic effects, numbers of seizures, and EEG abnormalities before and after treatment were observed. Results After the treatment, the numbers of seizures and EEG abnormalities in the two groups were significantly different compared with those before the treatments (P < 0.05). The efficiency of the treatment and control groups was 95.24% and 66.67% with the significant difference (P < 0.05). Conclusion Carbamazepine combined with Ningxian Powder could reduce the numbers of seizures with fewer adverse reactions, which is worthy of promotion.